Compare KRO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | JANX |
|---|---|---|
| Founded | 1916 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 975.7M |
| IPO Year | 2004 | 2021 |
| Metric | KRO | JANX |
|---|---|---|
| Price | $8.18 | $16.44 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $6.00 | ★ $47.00 |
| AVG Volume (30 Days) | 325.7K | ★ 813.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,859,400,000.00 | $10,000,000.00 |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | $90.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.08 | $12.12 |
| 52 Week High | $9.17 | $35.34 |
| Indicator | KRO | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 45.63 |
| Support Level | $5.97 | $13.00 |
| Resistance Level | $9.03 | $19.14 |
| Average True Range (ATR) | 0.39 | 0.77 |
| MACD | -0.13 | -0.27 |
| Stochastic Oscillator | 11.11 | 7.98 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The maximum of revenue comes from the United States.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.